Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Andreasen

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Acta Physiologica (Oxford, England)|February 2, 2011
Pregnancy protects against antiangiogenic and fibrogenic effects of angiotensin II in rat heartsM B Aljabri, N T Songstad, T Lund, et al.
Epidemics|April 7, 2015
Seven challenges in modeling vaccine preventable diseasesC J E Metcalf, V Andreasen, O N Bjørnstad, et al.
Vaccine|December 29, 2016
First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of ageLine M Lindgren, Pernille N Tingskov, Annette H Justesen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 20, 2013
The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practiceL M Søes, H M Holt, B Böttiger, et al.
The Lancet. Infectious Diseases|April 30, 2017
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trialLuis Rivera, Rasmus S Pedersen, Lourdes Peña, et al.
Basic Research in Cardiology|May 27, 2008
Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusionBritt N Fuglesteg, Naushaad Suleman, Crina Tiron, et al.
Vaccine|December 3, 2014
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in humanJaap T van Dissel, Simone A Joosten, Søren T Hoff, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Acta Physiologica (Oxford, England)|February 2, 2011
Pregnancy protects against antiangiogenic and fibrogenic effects of angiotensin II in rat heartsM B Aljabri, N T Songstad, T Lund, et al.
Epidemics|April 7, 2015
Seven challenges in modeling vaccine preventable diseasesC J E Metcalf, V Andreasen, O N Bjørnstad, et al.
Vaccine|December 29, 2016
First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of ageLine M Lindgren, Pernille N Tingskov, Annette H Justesen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 20, 2013
The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practiceL M Søes, H M Holt, B Böttiger, et al.
The Lancet. Infectious Diseases|April 30, 2017
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trialLuis Rivera, Rasmus S Pedersen, Lourdes Peña, et al.
Basic Research in Cardiology|May 27, 2008
Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusionBritt N Fuglesteg, Naushaad Suleman, Crina Tiron, et al.
Vaccine|December 3, 2014
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in humanJaap T van Dissel, Simone A Joosten, Søren T Hoff, et al.
Pageof 3